Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The p53 and nuclear factor-kappaB (NF-kappaB) pathways are critical in human cancer.
• Cancer often involves p53 inactivation and NF-kappaB hyperactivation.
• Activating p53 and inhibiting NF-kappaB induces apoptosis.

Purpose of the Study:

• To review small molecules with dual activity on p53 and NF-kappaB pathways.
• To explore the principles and mechanisms of these dual-acting compounds.
• To suggest future directions for developing dual-acting cancer drugs.

Main Methods:

• Literature review of existing research on p53 and NF-kappaB pathways.
• Analysis of small molecules exhibiting dual activity.
• Discussion of proposed mechanisms for dual action.

Main Results:

• Certain small molecules possess the ability to simultaneously activate p53 and inhibit NF-kappaB.
• These dual-acting molecules show potential for promoting cancer cell apoptosis.
• The review identifies candidate molecules and discusses their therapeutic implications.

Conclusions:

• Simultaneous modulation of p53 and NF-kappaB represents a promising therapeutic strategy for cancer.
• Further development of dual-acting small molecules could lead to novel cancer treatments.
• Targeting both pathways offers a concerted approach to cancer therapy.